GENMAB A/S (GMAB)
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Genmab A/S
1-25 of 565 filings
Recent SEC filings with analysis
- 6-KGenmab announced that its Phase 3 LiGeR-HN1 trial of petosemtamab plus pembrolizumab met both primary endpoints at the first interim analysis in first-line…
- 6-KGenmab announced that its Phase 3 RAINFOL-02 trial of rinatabart sesutecan (Rina-S) met its primary endpoint of progression-free survival and its key secondary…
- 6-KGenmab announced that worldwide net trade sales of DARZALEX (daratumumab) totaled USD 4,239 million in the third quarter of 2026, as reported by partner…
- 6-KGenmab A/S held an Extraordinary General Meeting on October 7, 2026, where shareholders approved the Board of Directors' 2026 remuneration proposal, including…
- 6-KGenmab and AbbVie announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial, showing epcoritamab plus R-CHOP achieved a statistically…
- 6-KGenmab A/S announced that Darwin Global Management Limited now controls voting rights attached to 3,188,361 Genmab shares, representing 5.11% of voting rights…
- 6-KGenmab A/S filed a 6-K disclosing the terms of its employee warrant schemes and a summary of all warrant grants issued through September 24, 2026 under board…
- 6-KGenmab A/S announced that its Board of Directors granted 13,794 restricted stock units and 13,331 warrants to employees of the company and its subsidiaries on…